CEO Corner

The CEO of Ovid Therapeutics, Jeremy Levin, feels no time has ever been better for biopharma leaders to speak out as part of their commitment to this industry.

Though biotechnology may never be as fast and efficient as software, we can make innovation and development faster — through nothing more than a Silicon-Valley way of thinking.

With gene therapy, we are at the dawn of another era of potentially rapid growth in the sector. And companies planning for their futures will once again consider a range of factors in identifying the optimal locations for gene therapy research and production centers.

All CEOs of small, publicly traded biotechs are required to wear many hats in the office every day. That’s why having a leader with a diverse background and experience in a variety of functional areas is an asset. Here we look at some of the various areas of expertise that can help create a more diverse C-suite executive.

Rich Daly, Chairman & CEO of Neuralstem, Inc., pens this month column and gives some enlightening anecdotes about what it takes to make "transformational" changes at a biopharma company.

Jeffrey Stein, Ph.D., president and CEO of Cidara Therapeutics, discusses what needs to be done now by drug companies and healthcare providers alike to stem the tide of emerging antimicrobial resistance, including collaboration to address market barriers.

I’ve often described the challenge of developing new medicines as analogous to the difficulty of climbing the highest mountains on Earth. If one follows that analogy, then seeking to develop a new treatment for Alzheimer’s disease is like climbing K2, the second highest peak — in winter.

Now is the time to develop a novel financial instrument which will provide risk transfer, transparency, and more certainty. A futures market in healthcare is a product whose time has come.

By its very definition, innovation may travel long and painful paths, require repeated failure, and invite numerous mistakes to gather experience for bringing forward something new. Lady luck also intervenes occasionally, as well.

Antibiotic resistance is a real and immediate threat that is beginning to garner the global attention it needs and deserves. During a meeting of the United Nations in September 2016, the entire General Assembly — 193 nations — reaffirmed its commitment to developing national action plans on combatting antibiotic resistance.